阿立哌唑口崩片治疗老年首发精神分裂症对照研究

A control study of aripiprazole orally distegrating tablets in se- nile first-episode schizophrenia

目的探讨阿立哌唑口崩片治疗老年期首发精神分裂症患者的临床疗效及安全性。方法将94例老年期首发精神分裂症患者随机分为研究组48例和对照组46例，研究组口服阿立哌唑口崩片治疗，对照组口服奋乃静治疗。观察8w。于治疗前及治疗第2w、4w、6w、8w末采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗8w末研究组显效率70．8％，总有效率为87．5％；对照组为67．4％、84．8％；两组比较无显著性差异（P〉0．05）。两组治疗第2w末阳性与阴性症状量表总分均较治疗前有显著下降（P均〈0．01），研究组较对照组下降更显著（P均〈0．05）；治疗8w末，总分及阴性因子、认知因子减分率均显著高于对照组（P〈0．05或0．01）。对照组不良反应发生率及副反应量表总分均高于研究组（P〈0．05或0．01）。结论阿立哌唑口崩片治疗老年首发精神分裂症疗效显著，与奋乃静相当，但阿立哌哗起效快，安全性高，依从性高，改善阴性症状、认知功能方面优于奋乃静治疗。

Objeceive To explore the efficacy and safety of aripiprazole orally distegrating tablets in senile first-episode schizophrenia. Methods 94 senile first-episode schizophrenics were randomly divided into research group（n=48） took aripiprazole orally distegrating tablets and control group（n=46） did perphena zinc for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale（PANSS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the end of the 2nd,4th,6th and8th week treatment. Results At the end of the 8th week,obvious and total effective rates were 70.8% and 87.5% in the research and 67.4% and 84.8% in the control group, respec tively, which showed no significant differences（P〉0.05）. At the end of the 2nd week, total score of the PANSS of both groups lowered more significantly compared with pretreatment （both P（0.01）, that did more significantly in the research than in the control group（P〈0.05）;at the end of the 8th week, total score and negative and cognitive factor score-decrement rate were all significantly higher in the research than in the control group（P〈0.05 or 0.01）. Incidences of adverse reactions and total score of the TESS were higher in the control than in the research group（P〈0.05 or 0.01）. Conclusion Aripiprazole orally distegrating tablets have an evident effect equivalent to perphenazine in senile first episode schizophrenia, the former take effects faster,have higher safety , better compliance and an advantage in improving negative symptoms and cognitive function over perphenazine.